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SUMMARY 
 
Introduction: Heparin is known to efficiently attenuate metastasis in various tumour models 
by different mechanisms including inhibition of tumour cell contacts with soluble and cellular 
components such as inhibition of heparanase or P- and L-selectin. We recently showed that 
heparin efficiently binds to VLA-4 integrin in melanoma cells in vitro. Here we describe VLA-4 
integrin as a mediator of melanoma metastasis that is inhibited by the low molecular weight 
heparin (LMWH) Tinzaparin.  
Materials and Methods: sh-RNA-mediated knock-down of VLA-4 integrin in B16F10 murine 
melanoma cells (B16F10-VLA-4kd) was performed and cell binding characteristics were 
investigated in vitro. Experimental metastasis of B16F10-VLA-4kd and B16F10 cells and 
interference by Tinzaparin were analysed in mice. 
Results: VLA-4 knock-down of B16F10 cells resulted in loss of VCAM-1 binding, but 
preserved the capacity to bind platelets through P-selectin. The observed reduced 
metastasis of B16F10-VLA-4kd cells confirmed the role of VLA-4 in this process. However, 
loss of melanoma VLA-4 function hardly further affected reduction of metastasis in P-selectin 
deficient mice. Tinzaparin treatment of mice injected with B16F10 and B16F10-VLA-4kd cells 
significantly reduced metastasis suggesting its potential to block both P- and L-selectin and 
VLA-4 in vivo. The use of N-acetylated heparin, which has no VLA-4 binding activity but 
blocks P- and L-selectin was less efficient than Tinzaparin in mice injected with B16F10 cells 
and B16F10-VLA-4kd cells.  
Conclusion: These findings provide evidence that heparin inhibits experimental melanoma 
metastasis primarily by blocking VLA-4 and P-selectin.  
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Abbreviations: 
FCS, fetal calf serum; FAK, focal adhesion kinase; LMWH, low molecular weight heparin; 
mAb, monoclonal Antibody; PBS, phosphate-buffered saline; PE labeled, Phycoerythrin 
labeled; PKCα, protein kinase C alpha; UFH, unfractionated heparin; VCAM-1, vascular cell 
adhesion molecule-1; VLA-4, very late activation antigen-4 
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INTRODUCTION 
 
The metastatic spread of solid tumours is the major cause for the poor outcome of cancer 
patients. The settlement of tumour cells in distant organs is commonly described as a 
metastatic cascade. Tumour cells detach from the primary tumour, migrate through the 
extracellular matrix, invade the blood circulation, interact with blood constituents, adhere to 
the endothelium, extravasate, and proliferate in distant tissues. Adhesion molecules mediate 
the critical interaction between tumour cells and the vascular endothelium as well as cellular 
and soluble blood components.  
The selectin family of vascular adhesion receptors has early been identified as key players in 
the metastatic process [1–3]. In the early phase of hematogenous metastasis P-selectin 
expressed on activated platelets and endothelium contributes to platelet-rich tumour cell 
emboli formation resulting in protection of tumour cells from innate immune system [4,5]. L-
selectin expressed by leukocytes facilitates the interaction of the tumour microemboli with the 
endothelium [6,7].  
Integrins are a larger family of adhesion receptors that facilitate the interaction of tumour 
cells with vasculature and circulating cells in the metastatic course. However, the exact role 
of integrins in this process remains under investigation. One member of this family is the very 
late activation antigen-4 (VLA-4, α4β1) expressed under physiological conditions on different 
subtypes of leukocytes, but is also found on melanoma, osteosarcoma, and 
rhabdomyosarcoma cells [8–11]. VLA-4 is able to bind to its ligand vascular cell adhesion 
molecule-1 (VCAM-1) expressed by activated endothelium thereby mediating adhesion and a 
subsequent transmigration of tumour cells [8,12]. Accordingly, VLA-4 contribution to 
metastasis has been demonstrated in several studies [13–15]. In addition, the enhanced 
expression of VLA-4 on melanomas correlates with poor clinical outcome [16–18]. A lot of 
efforts have been invested into inhibition of adhesion receptors of the selectin or integrin 
family and thereby intervention in metastasis [19].  
Heparin is routinely administered to cancer patients for an antithrombotic prophylaxis due to 
their increased risk for cancer-associated thrombosis. In a series of prospective clinical trials 
heparin has been shown to prolong survival of cancer patients especially those with initial 
better prognosis [20–24]. These effects were shown not only to be dependent on the 
antithrombotic properties of heparin, but on the capacity to reduce metastasis by inhibition of 
P- and L-selectin [25, 26]. In addition, several other anti-metastatic activities of heparin have 
been described including (i) inhibition of angiogenesis via stimulation of tissue factor pathway 
inhibitor (TFPI) release from the endothelium [27], (ii) modification of growth factors and 
chemokines binding to their receptors [28], (iii) inhibition of tumour cell secreted heparanase 
[29], (iv) potential interference with chemoresistance of cancer cells [30].  
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Furthermore, LMWH is apparently affecting intracellular signaling to downregulate the 
expression of FAK/p53 and PKCα which gave rise to a decrease in cell-substratum interface 
area, an alleviated melanoma cell migration, and an altered cell morphology [31,32].  
Earlier we demonstrated that heparin also binds to the integrin VLA-4 on melanoma cells and 
impedes the interaction with its endothelial ligand VCAM-1 in vitro. We performed several 
structure-activity correlations for several non-anticoagulant heparin derivatives based on 
chain length and sulfation degree [33]. Particularly, a N-acetylated heparin derivative was 
completely incapable to inhibit the VLA-4 adhesion but binds P- and L-selectin [33]. 
However, a LMWH such as Tinzaparin, appears most suitable to cover the anti-adhesive 
activities that is in line with the other anti-metastatic activities including anticoagulative 
effects. 
Although the role of VLA-4 in melanoma metastasis has been approached before [12–15], 
the potential of heparin to inhibit metastasis through blocking VLA-4 interactions has not 
been explored until now. In the present study we demonstrate for the first time that heparin 
interference with VLA-4 reduces the metastatic dissemination of melanoma cells. Inhibition 
with LMWH Tinzaparin or a non-VLA-4 binding heparin derivative provides evidence that the 
VLA-4 inhibition is critical for attenuation of experimental melanoma metastasis.  
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MATERIALS and METHODS 
 
Chemicals and proteins 
Recombinant human VCAM-1-Fc chimera, anti-human P-selectin mAb, control mAb, anti-
mouse integrin CD49d mAb (Phycoerythrin (PE)-labeled), and thrombin receptor activator 
peptide 6 (TRAP-6) were purchased from R&D Systems (Wiesbaden-Nordenstadt, Germany). 
Tinzaparin was obtained from LEO Pharma GmbH (Neu-Isenburg, Germany). Bovine serum 
albumin (BSA), sepharose® 4B, and cyanuric chloride were from Sigma-Aldrich (Deisenhofen, 
Germany), and Calcein-AM from Molecular Probes Europe BV (Leiden, Netherlands). The N-
acetylated heparin derivatives were prepared as previously described [34]. 
 
Cell culture 
The murine melanoma cell line B16F10 was kept in D-MEM with 4.5 g/L glucose 
supplemented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine and 1% (v/v) 
penicillin-streptomycin solution. To reduce the constitutive VLA-4 expression, a sh-RNA 
technique was applied for a continuous downregulation. B16F10 cells were transfected with 
a commercial available shRNA-plasmid (Mission® shRNA, Sigma-Aldrich), which was 
amplified in E. coli and isolated by Maxi-Prep (Sigma-Aldrich). Additionally, cells were 
transfected with a control plasmid merely coding for puromycin resistance. Lipid-based 
transfection was performed with FuGene®6 (Roche Applied Science), DNA-lipid ratio has 
previously been determined by GFP-plasmid transfection. To select transfected cells 
expressing anti-VLA-4-shRNA, a permanent puromycin treatment was performed. The VLA-4 
expression level in transfected cells was ascertained by flow cytometry (FACS Calibur, BD 
Heidelberg, Germany) using a PE-labeled anti-mouse integrin CD49d mAb.   
bEnd.3 cells were cultivated in D-MEM with 4.5 g/L glucose supplemented with 10% (v/v) 
heat-inactivated FCS, 2 mM L-glutamine and 1% (v/v) penicillin-streptomycin solution. 
 
Platelet isolation and cell platelet interaction 
Blood was collected from healthy volunteers in 15 mL tubes containing 1.6 mg potassium 
EDTA/mL blood. Afterwards, blood was centrifuged at 200 g for 20 min at 20°C to gain 
platelet-rich plasma. Separation of platelets from plasma proteins was conducted by gel 
filtration through a sepharose® 4B column. For adhesion experiments and for viability 
determination, platelets were labeled with 5 μg/5 mL Calcein-AM for 30 min at 37°C. 
Platelets were activated using TRAP-6 at a concentration of 5 µM for 15 min at 37°C. To 
compare the adhesion of B16F10 wild type (B16F10) and B16F10 VLA-4 knock-down 
(B16F10-VLA-4kd) cells to platelets either under static or dynamic conditions the following 
protocols were applied: i) Platelets were labeled, activated as described above, adjusted to a 
concentration of 1×108 platelets, and added to 1×106/100 μL cell suspension. After addition 
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of 5 µg of anti-P-selectin mAb, control mAb, or 500 µg Tinzaparin, the mixture was incubated 
for 5 min at 37°C under gently shaking. After dilution with 800 μL PBS, the cell platelet 
interaction was determined by flow cytometry.   
ii) Labeled and activated platelets (1×108) were added to a confluent layer of B16F10 or 
B16F10-VLA-4kd cells in 24-well cell culture plates alone or in presence of mAbs or 
Tinzaparin, mild shaked for 15 min, washed twice with PBS and the adherent platelets were 
counted with fluorescence microscopy.  
 
Adhesion under static conditions 
Calcein-labeled B16F10, B16F10 control cells, or B16F10-VLA-4kd cells (1×105) cells were 
added to a confluent layer of bEnd.3 cells in a total volume of 200 µL PBS in a 96 well plate 
and allowed to sediment for 15 min under gently shaking conditions. After washing twice with 
200 µL PBS, the adherent cells were quantified using a POLARstar Galaxy plate reader 
(BMG Labtech).    
 
Transmigration of B16F10 
Migration assays were performed in a 96 well transwell containing 8 μm pore-size inserts 
(Corning, Corning, NY) coated with gelatine (Sigma-Aldrich, Deisenhofen, Germany), 
overgrown with bEnd.3 endothelial cells. bEnd.3 cells (1×104) were cultivated for 2 days to 
form a confluent layer in 50 µL medium. 5 × 104 B16F10, B16F10 control, or B16F10-VLA-
4kd cells in 50 μL medium containing 1% (v/v) FCS were cultivated in the top compartment 
and exposed to chemotactic attraction by 10% (v/v) FCS in the medium in the bottom 
chamber. 
The chambers were incubated at 37°C in humidified air with 5% CO2 for 24 hours. Migrated 
cells were labeled with 2 mM Calcein-AM (Molecular Probes) in 0.02 % EDTA solution 
(Sigma-Aldrich, Deisenhofen, Germany) at 37°C for 1 hour and quantified in a POLARstar 
Galaxy plate reader (BMG Labtech). Results are expressed as mean ± SD from six technical 
replicates. Cells were incubated with neutralizing anti-VLA-4 antibodies (R&D Systems) for 5 
minutes prior start of the experiment. 
 
Flow chamber assay 
The interaction of B16F10 and B16F10-VLA-4kd cells with the ligand VCAM-1 was 
investigated under physiological flow conditions in a parallel plate flow chamber as described 
before [35,36]. Briefly, VCAM-1 Fc chimera (0.2 μg) was coated on glass slides which were 
incorporated into a parallel plate flow chamber and mounted on an inverted microscope.  
Flow medium, PBS (pH 7.4), was applied with a shear rate of about 200 s-1.  
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B16F10 and B16F10-VLA-4kd cells (1×106) were suspended in FCS-free medium and 
stimulated with 1 mM Mn2+ for 5 min at 37°C (stimulated cells) in comparison to unstimulated 
cells. Activation of VLA-4 with Mn2+ is an experimentally accepted approach to induce strong 
upregulation of integrin binding affinity as alternative to activation by mediators like 
chemokines,  in vitro [37]. 
After application into the flow chamber, cell adhesion was observed for a period of 5 s while 
video sequences were recorded with the camera CSC-795 (Pacific Corporation, Tokyo, 
Japan). Videos were evaluated with Imagoquant MultiTrack-AVI-2 software (Mediquant 
GmbH, Lützen, Germany). In some experiments Tinzaparin (50 µg) was added to test its 
inhibitory capacity towards the VLA-4/VCAM-1 interaction. 
 
Animal experiments 
P-selectin-deficient mice (P-sel-/-) in a C57BL/6J background and control wild-type (wt) 
C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). 
C57BL/6J or P-sel-/- mice were intravenously injected with 67 IU of Tinzaparin or 150 µg of N-
acetylated heparin, followed by injection of B16F10 or B16F10-VLA-4kd cells (1.5x105) 
through the tail vein 10 min later. After 14 days mice were euthanized, metastatic foci were 
counted and macroscopic pictures of lungs were taken. Mice were fed standard chow and 
water ad libitum and maintained on a 12-hour light/dark cycle. All animal protocols were 
approved by the Zürich Kantonal committee. 
 
Statistics 
Data are represented as mean ± standard deviation of at least three independent 
experiments. Comparisons were performed by the unpaired Student´s t-test. 
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RESULTS 
 
Impact of VLA-4 on B16F10 cell adhesion in vitro and transmigration 
To investigate the relevance of VLA-4 for metastatic dissemination of tumour cells we chose 
the highly metastatic murine melanoma cell line B16F10 that constitutively expresses VLA-4. 
B16F10 cells strongly adhered to immobilized VCAM-1 under physiological flow conditions 
[35]. Using shRNA approach we prepared VLA-4 knock-down cells, B16F10-VLA-4kd, which 
displayed a VLA-4 downregulation of up to 40 % compared to the wild type cells as 
determined by flow cytometry (Fig. 1A). B16F10 cells transfected with a control plasmid 
(B16F10 control cells) as expected had no effect.  
The functional consequence of reduced VLA-4 expression for binding to immobilized 
VCAM-1 was evaluated under dynamic flow conditions using a flow chamber, detecting the 
Mn2+ activated cells. 
B16F10-VLA-4kd cells showed a significantly reduced binding compared to B16F10 cells 
(Fig. 1B). After 4 sec of flow, 80 % of the Mn2+ activated B16F10 cells still adhered to the 
VCAM-1 layer whereas only 20 % of the B16F10-VLA-4kd clone cells were still attached, 
which was similar to adhesion of unstimulated B16F10 cells (15 %). Accordingly, Mn2+ 
stimulated B16F10 control cells possessed a similar binding behaviour like B16F10 cells 
(79 %). Despite the incomplete down-regulation of VLA-4 expression, B16F10-VLA-4kd cells 
were unable to adhere to VCAM-1 under flow condition. This indicated that a minimum of 
VLA-4 density on the cell surface must be sustained to keep a complete adhesion function. 
Furthermore it became evident that unstimulated B16F10 cells retain a certain residual VLA-
4 activity, since unstimulated B16F10-VLA-4-kd cells revealed a further reduction in binding 
to VCAM-1 after 4 s of flow (5 %) compared to unstimulated B16F10 cells.  
Application of Tinzaparin revealed a complete block of VLA-4 adhesion receptors both on 
stimulated B16F10 and B16F10-VLA-4kd cells reducing the cell adhesion to unstimulated 
B16F10-VLA-4kd cells. To approach more physiological binding conditions, we further 
investigated the impact of VLA-4 downregulation on endothelial contact formation and 
transmigration of B16F10 melanoma cells. 
 In a first step the binding of B16F10 cells to a bEnd.3 endothelial layer was analysed under 
static conditions (Fig. 1C). Both, VLA-4 and P-selectin contribute to endothelial interaction of 
the B16F10 cells, which was confirmed by application of mAbs against VLA-4 and P-selectin. 
Accordingly, B16F10-VLA-4kd cells failed to adhere to the bEnd.3 layer and displayed 
binding comparable to the non-activated cells (0.57 +/- 0.02 compared to 0.65 +/- 0.15). 
Antibodies against VLA-4 and P-selectin reduced binding to bEnd.3 cells of both B16F10 and 
B16F10-VLA-4kd cells in a similar ratio, whereas P-selectin seems to contribute to cell 
adhesion to a greater extent than VLA-4.  Tinzaparin, as an inhibitor of both VLA-4 and P-
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selectin, blocked efficiently binding of B16F10 cells (0.35 +/- 0.07). The expected 
predominance of Tinzaparin to block B16F10 binding compared with the antibodies was not 
displayed in this assay, apparently due to preincubation of B16F10 cells with Tinzaparin. 
Although VLA-4 on B16F10 cells can efficiently be blocked by Tinzaparin, it has to compete 
with high affinity P-selectin ligands on B16F10 cell for P-selectin binding on endothelial cells. 
Therefore a complete P-selectin inhibition is not ensured, as clearly evident in case of the 
B16F10-VLA-4-kd cells. 
To simulate further steps in the metastatic process, we tested the transmigration efficiency of 
B16-VLA-4kd through endothelial cells (Fig. 1D). The B16F10-VLA-4-kd displayed a reduced 
transmigration rate (0.67 +/- 0.02) compared with B16F10 cells (1.0 +/- 0.1), which indicates 
the importance of VLA-4 for both, contact formation and transmigration.   
Next we asked whether the VLA-4 downregulation has any impact on the selectin binding of 
B16F10-VLA-4kd clone cells. P-selectin and L-selectin were previously shown to facilitate 
metastasis of melanomas [29]. Therefore, we analysed the interaction of activated, P-selectin 
expressing platelets with B16F10 and B16F10-VLA-4kd clone cells (Fig. 2). First we 
analysed the platelet-melanoma interactions under static conditions using fluorescence 
microscopy (Fig. 2A). Platelet activation with TRAP-6 enhanced their binding to the cell layer 
of B16F10, B16F10 control cells and B16F10-VLA-4kd clone cells to a similar extent of 
approximately 60 platelets per view field. Administration of an anti-P-selectin mAb almost 
abrogated the platelet interaction with melanomas compared to a control mAb, thereby 
confirming the P-selectin dependency of platelet-melanoma cell interactions. Similarly, 
Tinzaparin, a known inhibitor of P-selectin, blocked the interactions of platelets with 
melanomas to the same extent as anti-P-selectin mAb. To ascertain that platelet interaction 
with tumour cells is also valid under dynamic conditions, flow cytometry experiments were 
performed. The data confirmed the results received under static conditions (Fig. 2B). B16F10, 
B16F10-VLA-4kd, and B16F10 control cells showed an identical binding to activated platelets, 
and the use of Tinzaparin or the P-selectin mAb (data not shown) reduced binding to 
melanomas.  
Taken together, the tumour cell-platelet interaction is P-selectin mediated, sensitive to 
Tinzaparin and not affected by VLA-4 downregulation. Thus, we confirmed that the B16F10-
VLA-4kd cells are suitable to differentiate between VLA-4-dependent and P-selectin-
dependent binding which will enable us to study the inhibitory potential of heparin in vivo.  
 
 
VLA-4 mediates experimental metastasis of B16F10 
To evaluate the involvement of VLA-4 on B16F10 during hematogenous metastasis, we 
intravenously injected C57BL/J6 mice with 1.5×105 B16F10, B16F10-VLA-4kd cells, or 
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B16F10 control cells, respectively. Mice were terminated after 14 days and the number of 
pulmonary metastatic nodules was determined (Fig. 3). While mice injected with B16F10 or 
B16F10 control cells showed almost displaced lungs with metastasis, injection of B16F10-
VLA-4kd cells resulted in a significant reduction of metastatic foci. These results clearly 
confirm VLA-4 as a key player in experimental B16F10 melanoma metastasis. 
 
 
Differentiation between P-selectin and VLA-4-mediated melanoma metastasis 
There is a large body of evidence that P-selectin and L-selectin facilitate metastasis of 
tumour cells when they are still in the circulation [4,6]. Therefore, we aimed to differentiate 
between the contribution of tumour cell-derived VLA-4 and selectin ligands to metastasis of 
B16F10 melanoma. We injected B16F10 or B16F10-VLA-4kd cells to P-selectin deficient 
mice. We observed significant attenuation of metastasis with both cells indicating that in the 
absence of P-selectin, VLA-4 presence or absence did not have a statistically significant 
effect on the reduced number of metastatic nodules (Fig. 4).  
 
 
Tinzaparin as an inhibitor of P-selectin and VLA-4-mediated interactions  
Next we assessed the anti-metastatic activity of heparin with the aim to compare VLA-4 
inhibition to P-selectin inhibition. We recently provided evidence that LMWH Tinzaparin has a 
high affinity binding to P-selectin and VLA-4 in the low micromolar range [33].  
We injected wild type mice with 67 IU of Tinzaparin 10 min prior to injection of B16F10 or 
B16F10-VLA-4kd cells. Tinzaparin treatment of mice almost abolished experimental 
metastasis of B16F10 and B16F10-VLA-4kd cells (Fig. 5). Next we injected P-selectin 
deficient mice with Tinzaparin prior to application of B16F10 or B16F10-VLA-4kd cells (Fig 4). 
Tinzaparin treatment further reduced metastasis to background levels indicating that other 
biological activities beyond adhesion (e.g. coagulation) are also part of antimetastatic 
treatment. 
To further dissect the role of VLA-4 and P-selectin inhibition during metastatic seeding, we 
tested a N-acetylated heparin derivative, which failed to bind to VLA-4, but preserves P- and 
L-selectin binding capacity [29,33]. N-acetylated heparin treatment of mice injected with 
B16F10 cells was less efficient than Tinzaparin which emphasizes a metastasis-contributing 
role of melanoma derived VLA-4, as indicated in Fig.3. In addition, N-acetylated heparin 
treatment of mice injected with B16F10-VLA-4kd cells resulted in a further but not significant 
reduction of metastatic burden, however not to the level reached by Tinzaparin treatment. 
Together, these findings provided evidence that inhibition of P-selectin is the major anti-
10 
 
metastatic activity of Tinzaparin, while inhibition of VLA-4-mediated interactions further 
blocks metastatic spread.  
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DISCUSSION 
 
The anti-metastatic activities of heparin have been a matter of intensive research during the 
last decade and research on therapeutic potential is still ongoing. Several molecular 
mechanisms of heparin have been described and also have been experimentally confirmed. 
Inhibition of coagulation seems to be a basis for heparin activities, also in blocking 
metastasis. Despite a great variation in the tested tumour models, the blockade of P- and L-
selectin appears also as an important target of heparin [25]. This opinion further underlined 
the importance of cellular adhesion receptors in the metastatic cascade and their role as 
therapeutic targets.      
Compared to selectins, the receptor family of integrins is ubiquitously expressed by virtually 
all cells, and different integrin pairs are involved in variety of cellular processes [38]. However 
their role during cancer metastasis is less defined and studied.   
Here we studied the role of VLA-4 integrin in melanoma metastasis and evaluated the 
inhibitory potential of heparin. Several melanoma cells express high levels of the integrin 
VLA-4 on their surfaces [11]. The relevance of VLA-4 interaction with VCAM-1 on the 
endothelium during metastatic spread has been shown by several groups in the early 90s 
[13–15]. Accordingly, VLA-4 was proposed as a target for interference in the metastatic 
cascade. Nevertheless, VLA-4 has attracted more attention as a target for autoimmune 
diseases like multiple sclerosis, where a blocking antibody has been approved for 
therapy [39]. 
Recently we provided evidence for a heparin capacity to bind VLA-4 [35]. Although we 
described numerous structure-activity relationships of heparin-VLA-4 binding [36] the 
relevance of this interaction has never been addressed in vivo. Here we show that VLA-4 on 
murine melanoma cell line B16F10 contributes dominantly to its experimental metastasis. 
Furthermore, we provide evidence for the first time that a LMWH - Tinzaparin - blocks VLA-4 
in vivo thereby reducing the metastatic dissemination of melanoma cells. Although these 
findings have been conducted in an experimental metastasis assay, certain effects of 
metastasis formation (an impact of microenvironment) are not adequately reflected, these 
data allude to a novel physiologically relevant mechanism how heparin interferes with 
experimental metastasis. However, we acknowledge that a spontaneous metastasis model 
would be more relevant to the clinical setting. 
We show that integrin and P-selectin are two adhesion mechanisms involved in metastatic 
spread. Our results indicate that in the P-sel-/- background, VLA-4 only has a minimal and not 
significant additional contribution to the establishment of metastatic foci and that P-selectin is 
dominant over the integrin VLA-4 which was also confirmed under in vitro conditions.  
VLA-4 mediates endothelial arrest of melanoma cells that is supported by P-selectin-
mediated tumour cell emboli formation. Interestingly, Tinzaparin almost completely 
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attenuates metastasis of both wt B16F10 and B16F10-VLA-4kd cells. This is in agreement 
with the capacity of Tinzaparin to affect both P-selectin and VLA-4 binding. However, N-
acetylated heparin has only capacity to bind P-selectin but not VLA-4 and is non-
anticoagulant [33]. Accordingly, N-acetylated heparin attenuated metastasis of B16F10 cells 
less efficiently compared to Tinzaparin. Nevertheless a significant decrease in the number of 
metastatic foci was observed in mice injected with B16F10-VLA-4kd cells and treated with N-
acetylated heparin blocking P-selectin compared to non-treated controls. These results 
indicate that both P-selectin and VLA-4 mediated interactions significantly contribute to 
metastatic spread of melanoma cells. 
Tinzaparin treatment almost completely inhibited metastasis, indicating additional biological 
activity beyond inhibition of cell adhesion. Tumor-induced coagulation has a significant role in 
thrombus formation that is associated with cancer progression [40,41]. However, Tinzaparin 
treatment of mice at clinically relevant concentration was clearly beneficial over a specific 
anti-thrombotic treatment, Fondaparinux, strongly suggesting that inhibition of coagulation is 
not significantly contributing to anti-metastatic activity in a mouse model of experimental 
metastasis [42]. Here we provide a direct comparison of Tinzaparin with modified heparins 
(N-acetylated), which has reduced biological activities. Clearly, Tinzaparin has additional 
beneficial effect over N-acetylated heparin on metastasis, which will be the focus of further 
investigations. 
Our findings describe an important role of integrin VLA-4 engagement on tumour cells by 
blood components and endothelium during hematogenous spread. However, VLA-4 seems 
to be also involved in melanoma transmigration through the endothelial cells in vitro. Since 
integrins are bidirectional signalling molecules, heparin-integrin interaction may also have 
further consequences beyond the adhesion. Integrins are also involved in the crosstalk with 
numerous classes of growth factor receptors and cytokine receptors and are able to mediate 
proangiogenic and proliferative signals to the tumour cells [43–47]. On contrary, integrins can 
also initiate pro-survival and pro-tumourigenic as well as pro-apoptotic signals [44,48,49]. 
The activation of each pathway depends on the ligation status of the integrins by a given cell. 
In cells in which most of the integrins are ligated, pro-survival signals were reported whereas 
pro-apoptotic signals were found in unligated cells [50,51]. The role of heparin in this 
complex network will be addressed in future studies.  
Concluding, our data introduce VLA-4 as a key player in B16F10 melanoma experimental 
metastasis, which can efficiently be blocked by the LMWH Tinzaparin, whereby reducing the 
metastatic burden. Furthermore, not only VLA-4 expressing tumour cells should be 
addressed by these findings. Recent reports revealed further functionalities of VLA-4 and 
VCAM-1 in the metastatic microenvironment, which are beyond a direct tumour cell contact 
with the endothelium. For instance, in VCAM-1 expressing breast tumour cells a pro-survival 
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signalling is induced upon binding to macrophages via VLA-4. In addition, VCAM-1 positive 
breast tumour cells metastasizing to the bones decoy VLA-4 osteoclast progenitors whereby 
promoting destruction of the bone matrix [52,53] Also the recruitment of myeloid cells that 
promote pulmonary metastasis in mice has revealed to be VLA-4/VCAM-1 dependent [54]. 
Hence, VLA-4 is involved in the metastatic niche in multiple facets, so our findings give a 
novel input for therapeutic strategies to target VLA-4 dependent metastatic pathways by 
heparin. 
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Legends to Figures: 
 
Figure 1: Functional consequences of a VLA-4 knock-down on adhesion and 
transmigration of B16F10 cells to immobilized VCAM-1 under flow conditions. A) 
B16F10, B16F10 control cells, and B16F10-VLA-4kd were incubated with an anti-mouse 
VLA-4 mAb (PE labeled) and investigated with flow cytometry. B16F10 and control cells 
expressed comparable levels of VLA-4 on their surfaces, whereas B16F10-VLA-4kd display 
a VLA-4 downregulation by 40% compared to B16F10 cells. B) B16F10, B16F10 control 
cells, or B16F10-VLA-4kd cells (1×106/100 μL medium) were put into the flow chamber (in 
some cases after stimulation with 1 mM Mn2+) and allowed to sediment for 5 min. After this 
period, the flow was started and the adhesion behaviour was monitored over the indicated 
time range. B16F10 and B16F10 control cells displayed a similar adhesion after Mn2+ 
stimulation, whereas B16F10-VLA-4kd cells showed a significantly reduced binding 
approximating the level of unstimulated B16F10 cells. Application of Tinzaparin also reduced 
the binding to the same level of unstimulated B16F10-LAV-4kd cells. C) Calcein-labeled 
B16F10 or B16F10-VLA-4kd cells (1×105) cells were added to a confluent layer of bEnd.3 
cells in a total volume of 200 µL PBS in 96 well plate and allowed to sediment for 15 min. 
After washing twice with PBS, the adherent cells were quantified in a plate reader. B16F10-
VLA-4kd cells as well as the application of an anti-VLA-4 mAb, anti-P-sel-mAb, or Tinzaparin 
displayed a reduced binding to bEnd.3 cells. D) Transmigration of B16F10 or B16F10-VLA-
4kd cells through a confluent layer of bEnd.3 cells was determined using a boyden chamber 
approach with a FCS gradient (for details see Materials and Methods). A VLA-4 knock-down 
and application of an anti-VLA-4 mAb reduced transmigration up to 40% compared with 
B16F10 cells.   
Data are presented as mean values ± SD (n≥5; *** p<0.001 with respect to stimulated 
B16F10 cells). 
 
 
Figure 2: P-selectin dependent interaction of B16F10 and B16F10 clone cells to 
platelets under static and dynamic conditions. A) B16F10, B16F10 control, or B16F10-
VLA-4kd cells were incubated either with unstimulated or TRAP-6 activated platelets  
(1×108). Stimulated platelets showed an augmented adhesion to the cells. This interaction 
could be abrogated by adding a P-selectin binding mAb (5 µg) or Tinzaparin (500 µg), 
respectively. A control mAb (5 µg) had no influence on tumour cell platelet interaction. 
B16F10, B16F10 control, and B16F10-VLA-4kd cells showed nearly an identical adhesion 
behavior (n.d., no differences between B16F10, B16F10 control cells, and B16F10-VLA-4kd 
detectable). 
B) Detached B16F10, B16F10 control, or B16F10-VLA-4kd cells were incubated with TRAP-
6 activated (a.p.) and resting platelets (u.p.) (1×108) for 5 min under gently shaking 
conditions and then determined by flow cytometry. B16F10 and both clones showed no 
differences in fluorescence intensity indicating similar platelet interaction capacities. 
Tinzaparin reduced the tumour cell platelet interaction approximating the behaviour of resting 
platelets. One representative of three comparable results is shown here. 
 
 
 
Figure 3: Elucidation of VLA-4 mediated metastasis in an experimental mouse model. 
Mice were killed 14 days after tumour cell inoculation into the tail vein (B16F10, B16F10 
control, or B16F10-VLA-4kd cells) and pulmonary metastatic burden was determined. 
B16F10-VLA-4kd cells reveal a bisection of metastases compared to B16F10 cells. 
 
 
Figure 4: Differentiation of VLA-4, P- and L-selectin contribution to hematogenous 
metastasis. B16F10 or B16F10-VLA-4kd cells were injected into P-sel -/- mice and after 
termination the pulmonary metastatic foci were quantified. Some mice were treated with 67 
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IU of Tinzaparin prior to tumor cell injection. Mice administered with B16F10-VLA-4kd cells 
displayed a slight decrease in number of metastases due to VLA-4 knock-down and 
remaining L-selectin function.  
 
 
Figure 5: Inhibition of metastasis due to Tinzaparin and N-acetylated heparin 
application. Wild type mice were intravenously injected with 67 IU of Tinzaparin or 150 µg of 
N-acetylated heparin, followed by injection of B16F10 or B16F10-VLA-4kd cells (1.5x105) 
through the tail vein 10 min later. After euthanization, for all three groups metastatic nodules 
were hardly detectable and tend to zero due to a P- and L-selectin, and VLA-4 inhibition by 
Tinzaparin and a P- and L-selectin blockade mediated by the N-acetylated heparin 
derivative.  
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